Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.47EUR
−24.49 MEUR
50.12 M
About Corvus Pharmaceuticals, Inc.
Sector
CEO
Richard A. Miller
Headquarters
Burlingame
Website
Employees (FY)
28
Founded
2014
FIGI
BBG00CLG1B62
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of C17 is 1.71 EUR — it hasn't changed in the past 24 hours. Watch CORVUS PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CORVUS PHARMACEUTICALS INC stocks are traded under the ticker C17.
C17 stock has fallen by 0.58% compared to the previous week, the month change is a 12.83% fall, over the last year CORVUS PHARMACEUTICALS INC has showed a 16.89% decrease.
We've gathered analysts' opinions on CORVUS PHARMACEUTICALS INC future price: according to them, C17 price has a max estimate of 11.16 EUR and a min estimate of 3.25 EUR. Watch C17 chart and read a more detailed CORVUS PHARMACEUTICALS INC stock forecast: see what analysts think of CORVUS PHARMACEUTICALS INC and suggest that you do with its stocks.
C17 stock is 0% volatile and has beta coefficient of 1.79. Track CORVUS PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is CORVUS PHARMACEUTICALS INC there?
Today CORVUS PHARMACEUTICALS INC has the market capitalization of 106.28 M, it has decreased by 6.08% over the last week.
Yes, you can track CORVUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
CORVUS PHARMACEUTICALS INC is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
C17 earnings for the last quarter are −0.11 EUR per share, whereas the estimation was −0.13 EUR resulting in a 11.11% surprise. The estimated earnings for the next quarter are −0.11 EUR per share. See more details about CORVUS PHARMACEUTICALS INC earnings.
CORVUS PHARMACEUTICALS INC revenue for the last quarter amounts to 0 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
C17 net income for the last quarter is −5.28 M EUR, while the quarter before that showed −6.03 M EUR of net income which accounts for 12.34% change. Track more CORVUS PHARMACEUTICALS INC financial stats to get the full picture.
No, C17 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 1, 2024, the company has 28.00 employees. See our rating of the largest employees — is CORVUS PHARMACEUTICALS INC on this list?
Like other stocks, C17 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CORVUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CORVUS PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CORVUS PHARMACEUTICALS INC stock shows the buy signal. See more of CORVUS PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.